Navigation Links
Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
Date:1/13/2014

EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to develop a treatment for Ehlers-Danlos syndrome hypermobility type (EDS-HT), a rare genetic disorder resulting in weakened connective tissue.

Fibrocell and Intrexon will endeavor to engineer autologous fibroblast cells genetically corrected to produce tenascin-X (TN-X), a protein that is deficient in the connective tissue of a subset of EDS-HT patients.  Patients with EDS-HT often experience significant musculoskeletal complications, including frequent joint dislocations, subluxations and early onset osteoarthritis.

Jouni Uitto, M.D., Ph.D., Chair of the Department of Dermatology and Cutaneous Biology at Thomas Jefferson University in Philadelphia, Pennsylvania, said the collaboration is a step toward addressing the unmet needs of EDS patients around the world.

"There are currently no therapies for hypermobility-type EDS," said Dr. Uitto. "Healthcare providers are only able to treat the severe symptoms of EDS, such as prescribing braces to improve joint stability and by assisting patients with the pain they experience.  The prospect of an actual treatment is wonderful news for these patients."

Fibrocell Chief Executive Officer David Pernock noted that the companies' evolving expertise and experience gained through the existing R
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
2. BioForce NanoSciences Adds Sixth Continent to Export List
3. Bayer CropScience to Share Insights on Unlocking New Canola Opportunities
4. Bayer CropScience Announces Darrin Dodds as the 2014 Extension Cotton Specialist of the Year
5. Capsugel’s Bend Research to Present New Processes for Flu Vaccine and Other Science Advancements at Upcoming Industry Meetings
6. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
7. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
8. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
9. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
10. TwinLink Technology from Bayer CropScience Now Available for 2014 Growing Season in FiberMax and Stoneville Cotton Varieties
11. Bayer CropScience Offers Seven New Varieties for 2014, Four with GlyTol LibertyLink TwinLink Technology for Weed and Insect Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Research and Markets ... "Global DNA Diagnostics Market (Product types, Application, Technology, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. This ... techniques, end users and Geography) Global Size, Industry ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... The organizers of Pharma,ChemOutsourcing Conference & Exhibition ... and biotech company speakers who,will gather in ... around the,exploding chemical outsourcing activities reshaping R ... industry, reports Apaporis LLC. The,conference program may ...
... 2 ev3 Inc. (Nasdaq:,EVVV), a global endovascular device ... of 2008 and its revised financial,guidance for 2008., ... in the,first quarter of 2008 representing a 65% increase ... 10% increase over the fourth quarter of 2007. The,increase ...
... The timing of the live teleconference should have read: "9:00 am ... follows: Resverlogix Notice ... ... pleased to announce that it will host a live,teleconference on May 8, 2008 at ...
Cached Biology Technology:Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 3ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 4ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 5ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 6ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 7ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 8ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 9ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 10ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 11ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 12/C O R R E C T I O N from Source -- Resverlogix Corp./ 2
(Date:10/22/2014)... Calif. , Oct. 20, 2014 The ... United States Air Force Research Laboratory (AFRL), has chosen ... Medicine (AzCIM) at the University of Arizona College of ... research funding.  The AzCIM project,s goal is to assess ... to collect different volumes of sweat under a variety ...
(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... Ill. (March 28, 2011)Deep vein thrombosis, or DVT: it,s ... long plane ride. The Society of Interventional Radiology wants ... serious condition, which can lead to post-thrombotic syndrome, pulmonary ... "Individuals and their doctors need to be ...
... of Utah scientists used invisible infrared light to make ... signals to the brain. The discovery someday might improve ... restore vision, maintain balance and treat movement disorders like ... with optical infrared pulses instead of electrical pulses," which ...
... Researchers have described how the most common gene ... of cancer development and how it can cooperate with ... leukaemia. The researchers suggest that three critical steps ... ones, each subverting a different cellular process. By charting ...
Cached Biology News:Interventional radiologists take lead on reducing disability from dangerous blood clots 2Interventional radiologists take lead on reducing disability from dangerous blood clots 3Interventional radiologists take lead on reducing disability from dangerous blood clots 4Will we hear the light? 2Will we hear the light? 3Will we hear the light? 4Will we hear the light? 5The gene processes that drive acute myeloid leukaemia 2The gene processes that drive acute myeloid leukaemia 3
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Biology Products: